Oragenics Inc. (NYSE American: OGEN), a clinical-stage biopharmaceutical company developing neurological therapeutics, has received a critical reprieve from NYSE Regulation. The exchange accepted the company's compliance plan and granted an extension through Feb. 25, 2028, to regain compliance with NYSE American continued listing standards. The approval allows Oragenics to maintain its exchange listing while implementing measures intended to strengthen its financial position, subject to meeting plan milestones and ongoing review requirements.
The extension matters because a NYSE American listing provides access to capital markets and institutional investors that would be difficult to replicate on over-the-counter venues. Oragenics received a noncompliance notice on Aug. 26, 2026, after reporting stockholders' equity of $3.7 million as of June 30, 2026, and losses from continuing operations and/or net losses in its five most recent fiscal years. The company submitted its compliance plan on Sept. 25, 2026, and received formal acceptance on Nov. 11. With the extension in hand, Oragenics avoids an immediate delisting process that could have disrupted its operations and financing strategy.
CEO Janet Huffman said the extension will allow Oragenics to continue pursuing its strategic priorities, capital-raising initiatives and investment strategies aimed at enhancing long-term shareholder value. That flexibility is especially important for a company whose lead asset, ONP-002, is a potential first-in-class treatment for concussion and mild traumatic brain injury delivered through proprietary intranasal technology. Oragenics is working on commencing clinical trials in Australia for ONP-002, with U.S. Phase 2b trials planned to follow, and its intranasal delivery platform has potential applications across multiple neurological conditions, including Parkinson's disease, Alzheimer's disease, PTSD, and anxiety disorders.
The compliance extension does not resolve the underlying equity deficiency, and the company must still meet plan milestones under ongoing review. But it buys time for Oragenics to advance its pipeline and raise capital without the overhang of an imminent delisting. For investors tracking the company, the latest news and updates relating to OGEN are available in the company's newsroom at https://ibn.fm/OGEN, and the full press release can be viewed at https://ibn.fm/LiPlM. Additional information about the company is available at oragenics.com.
The announcement was distributed through BioMedWire, a specialized communications platform focused on the biotechnology, biomedical sciences and life sciences sectors. BioMedWire is one of more than 75 brands within the Dynamic Brand Portfolio at IBN, which provides wire solutions through InvestorWire and other corporate communications services. For full terms of use and disclaimers applicable to this content, see https://www.BioMedWire.com/Disclaimer.


